Trial Profile

A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC 703813, IND70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Rituximab (Primary)
Indications Follicular lymphoma
Focus Therapeutic Use
Acronyms Alliance; CALGB 50803

Most Recent Events

03 Aug 2022 Status changed from active, no longer recruiting to completed.
31 May 2020 Results establishing if BMB add value in assessing response or identify distinct progression free (PFS) or overall survival (OS) outcomes in a large, multicenter, multi-trial cohort presented at the 56th Annual Meeting of the American Society of Clinical Oncology
24 Apr 2019 Status changed from completed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com